To date, both monomeric form of soluble TRAIL (114–281) and dimeric DR4/DR5 agonist monoclonal antibody (mAb) approaches have yielded suboptimal therapeutic outcomes, even in combination with conventional anti-cancer drugs. This evidence concerns the gene TNFRSF10A and cancer.